Ipca Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ipca Laboratories, the promoter of Krebs Biochemicals, has submitted a routine annual declaration under SEBI's Takeover Regulations confirming that it has not created any encumbrance (pledge, lien, or charge) on the equity shares it holds in Krebs Biochemicals during the financial year ended March 31, 2025. This is a mandatory yearly filing required from promoters and persons acting in concert, not a new transaction. The declaration simply reaffirms that the promoter's holdings remain unencumbered.
No material impact on shareholders or stock price. This is a routine regulatory compliance filing that confirms the promoter's shares are free from any pledge or encumbrance, which is mildly positive for governance perception but does not change the ownership structure.